Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

DuPont ( DD) built a $34 billion annual chemical and materials business through innovation. The firm's labs have been the birthplace of technologies like Kevlar, Nomex, Tyvek, and Corian. More recently, though, DuPont has been carving out a lucrative niche in the agricultural chemical world, building up its genetically modified seed business and becoming one of the key suppliers of crop seeds in the world. That's helped to fuel double-digit margins in the bottom line and top-line numbers that have eclipsed pre-recession revenues in each of the last two years.

>>5 Stocks That Have Yet to Recover Form 2008

DuPont's considerable diversification is one of its most attractive attributes. Because the firm earns its sales across a handful of disparate industries, it's able to smooth out the cyclical ups and downs that usually harangue chemical companies. The acquisition of Danisco in 2011 furthers that diversification by adding a mature food additives business to the mix. New R&D efforts at Danisco to produce biofuels and a new synthetic rubber could add important new business to DuPont's books as well.

Because DuPont is a big ship to turn around, changes to the firm's sales mix have been relatively slow. Even so, there's a lot to like about a management team that is willing to forego near-term success in favor of longer-term profits. Right now, DuPont pays out a 3.34% dividend yield, enough to round out the top five Dogs of the Dow.

To see these stocks in action, check out the at Dogs of the Dow portfolio on Stockpickr.

-- Written by Jonas Elmerraji in Baltimore.


Follow Stockpickr on Twitter and become a fan on Facebook.

At the time of publication, author had no positions in stocks mentioned.

Jonas Elmerraji, CMT, is a senior market analyst at Agora Financial in Baltimore and a contributor to TheStreet. Before that, he managed a portfolio of stocks for an investment advisory returned 15% in 2008. He has been featured in Forbes , Investor's Business Daily, and on Jonas holds a degree in financial economics from UMBC and the Chartered Market Technician designation.

Follow Jonas on Twitter @JonasElmerraji

If you liked this article you might like

'Date' These Potential Biotech Winners

'Date' These Potential Biotech Winners

The 10 Stocks America's Biggest Hedge Funds Are Dumping Like Crazy

Why You Keep Cash on Hand; No Downside Conviction -- Jim Cramer's Top Thoughts